FDA Issues Public Health Advisory for Antipsychotic Drugs used for Treatment of Behavioral Disorders in Elderly Patients The Food and Drug Administration (FDA) today issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved (i.e., “off-label”) use of certain drugs called “atypical antipsychotic drugs.” […]
New FDA Labeling for Pfizer’s Celebrex and All Other NSAIDs to Reflect Similar Cardiovascular Profile
New FDA Labeling for Pfizer’s Celebrex and All Other NSAIDs to Reflect Similar Cardiovascular Profile Pfizer said today it will work with the U.S. Food and Drug Administration (FDA) to add expanded risk information in the Celebrex label following an FDA decision announced this morning to require boxed warnings of potential cardiovascular risk for all […]
FDA Announces Plans to Prohibit Sales of Dietary Supplements Containing Ephedra; Consumers Advised to Stop Using Ephedra Products Immediately
FDA Announces Plans to Prohibit Sales of Dietary Supplements Containing Ephedra; Consumers Advised to Stop Using Ephedra Products Immediately HHS Secretary Tommy G. Thompson today announced that the Food and Drug Administration (FDA) has issued a consumer alert on the safety of dietary supplements containing ephedra and has notified manufacturers of its intent to publish […]